Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SKRR Exploration Inc. V.SKRR

Alternate Symbol(s):  SKKRF

SKRR Exploration Inc. is a Canada-based precious metal explorer with properties in Saskatchewan mining jurisdictions. The Company's primary exploration focus is its three gold properties on the Trans-Hudson Corridor in Saskatchewan. The Company’s projects include Nickel Peak Group, Carp River, Manson Bay, Father Lake, Irving, Olson, Ithingo and Cathro. The Carp River property, comprised of five contiguous mineral claims totaling 5,606.48 hectares (ha), is located immediately north of the hamlet of Stony Rapids in the province of Saskatchewan. The 4,293 ha Manson Bay Project is located 40 kilometers (Km) northwest of Flin Flon, Manitoba’s historic mining center and four kilometers southwest of the Schotts Lake Copper-Zinc Deposit in Saskatchewan. The Father Lake property is located 40 km northeast of the hamlet of Stony Rapids in the province of Saskatchewan. The Ithingo Project consists of 12 contiguous mineral claims comprising an overall land package of approximately 2,849 hectares.


TSXV:SKRR - Post by User

Bullboard Posts
Post by DCArnoldon May 07, 2001 12:45am
303 Views
Post# 3704963

Conference call transcript part I

Conference call transcript part IConference call transcript part I Matt Emmens: Good morning, my name is Matt Emmens and I'm President and CEO of EMD Pharmaceuticals Incorporated which is a subsidiary of Merck KGaA of Darmstadt, Germany. We're here today with Alex McPherson who is President and CEO of Biomira which is a Canadian biopharmaceutical company. We have the privilege today of announcing a collaboration together that we're happy about, that we think can help cancer patients throughout the world. First of all, let me talk about the collaboration. The collaboration involves two important cancer vaccines, the first called Theratope, the second called BLP25. The first product is indicated for breast cancer, if the studies are successful; the second product will be for lung cancer. Two important cancers in the world. We're here today to talk about a collaboration that involves development worldwide, marketing, co-marketing in the United States and marketing for Merck and development for Merck throughout the world. These important vaccines, we hope, can help patients throughout the world in the next few years. Let me talk first about what EMD Pharmaceuticals is and make sure that we don't confuse Merck, the German pharmaceutical company with Merck & Company, the USA company. They have common history but Merck KGaA is located in Darmstadt, Germany and EMD Incorporated is located in Durham, North Carolina is the US ethical pharmaceutical division of Merck KGaA. With that, I would like to introduce Dr. Alex McPherson, President of Biomira. Dr. McPherson: Thanks very much, Matt. And thank you ladies and gentlemen for joining us, it's a great pleasure for me to be here on this important occasion for Biomira and, I believe, for EMD and Merck KGaA, as well. Biomira is a biotechnology company, which focuses on therapeutic cancer vaccines and on the development of innovative therapeutic approaches for the treatment of cancer. We intend to build a profitable company for our investors and we intend to do this, in part, through forward integration with such companies as Merck KGaA and EMD. This will be done predominately through the development of vaccines and related immunotherapeutic products primarily for the treatment of cancer. Biomira is extremely pleased to have entered into this global alliance with respect to co-promotion and collaboration with Merck KGaA with respect to our two most advanced products, Theratope for metastatic breast cancer, as Matt has said, and BLP25, for non-small cell lung cancer, the smoker's cancer. Theratope vaccine is a synthetic mimic, a carbohydrate or sugar of a particular molecule sialyl Tn and it's a naturally occurring molecule on cells, particularly the cells of the endothelium or the lining surface of a variety of different organs such as the gut and the breast and lungs. It's also found uniquely on cancer cells and it's because of the fact that it's a unique molecule on cancer cells that when combined with a carrier and injected with an adjuvant, it induces a very potent antibody response which we are looking at for stabilization of breast cancer and more importantly, on the basis of our phase II data, improved survival in patients with spread of their breast cancer after they've been treated with chemotherapy. We've just completed a 1030 patient phase III pivotal clinical trial for Theratope, 120 different sites in 11 countries. This is probably the largest immunotherapeutic trial ever conducted in the world. The trial is designed to test whether or not the vaccine can improve the time to progression of disease in women who have been treated with chemotherapy for their metastatic breast cancer and most importantly whether it can improve survival in those particular populations. The US Food and Drug Administration has, in fact, designated Theratope vaccine as a Fast Track program. BLP25 vaccine is our follow on product candidate is in phase IIb clinical trials in non-small cell lung cancer, the smoker's cancer. And this particular product is a peptide as opposed to a carbohydrate and in this case we're working with 25 amino acids, which are then encapsulated in a liposome or a fat droplet about the size of a red cell. It is believed that it enhances recognition of cancer cells by the immune response, which is predominately what is called a T cell response as opposed to the B cell response that Theratope induces. Earlier phase I and phase II trials, looking at BLP25, have shown exceptional safety, some early indication of efficacy. The current study is designed to show whether or not safety is maintained in the phase IIb trial as well as to see whether or not survival is improved. And this is critical because the median survival, for this horrible disease once it is at a stage IIIb or stage IV level, is only on the order of nine months. So, we certainly are working very hard in two of the major cancers, in the world, with respect to trying to improve survival in these patients, using a product which is relatively safe in comparison to virtually all other therapeutics that are currently available. Now the collaboration details relate to the fact that we will jointly market the products with Merck KGaA through EMD in the USA. We will retain marketing rights in Canada. Merck KGaA will have full development rights, marketing and development rights in the rest of the world with the exception of Israel and the Palestinian Autonomy Area, for which agreements were already in place. Biomira will receive an upfront equity payment as well as a cash payment and Biomira will also receive significant cash and equity payments with respect to our BLA or Biological License Applications, submissions for first and second cancer indications and for sales milestones. The total value of the agreement to Biomira exceeds US $150 million in license, milestone payments and equity investments plus sales and royalties. Biomira and Merck KGaA will share development costs in North America and Merck KGaA will be responsible for clinical studies and marketing outside of North America. Biomira is exceptionally pleased to be working through Merck KGaA in association with EMD with Matt here as the President and CEO of that particular wholly owned subsidiary. We will be manufacturing the vaccines for worldwide use and will be entitled to an equal share of product sales in the US and Canada and royalties on sales for all other territories. Matt Emmens: Thank you, Alex. And EMD and Merck KGaA are especially excited about the vaccines as it adds to our product development pipeline focused on oncology. Our primary focus in the US has been oncology; in fact we run the oncology business worldwide from the USA at EMD. Merck KGaA, as you know, is a large company. We have over 33,500 employees, we are in 52 countries throughout the world and we have over 200 operating companies. So, our size, our global ability to develop the drug and our ability to, in a short term, market the US given approval excites the many talented employees both at EMD and in Germany and in France where our two headquarters cities are. We'd be happy to take questions at this time and answer them the best we can. Announcer: Gentlemen, our first question is from the Internet and I think it goes to both of you. Question: What does each company bring to this collaboration? Matt Emmens: I would say Merck KGaA brings 330 years of pharmaceutical experience. It's the oldest pharmaceutical company on the face of the Earth. EMD is probably the newest pharmaceutical company in the United States but it brings the ability to globally develop and market these vaccines should they be successful in clinical trials. The focus on oncology that we have, with a preference towards biotherapeutics, allows us to be particularly interested in anything that stimulates the immune system to attack cancer. We think it's a certainly more targeted way, we're pretty sure it's a safer way and for patients that have these dreaded diseases, a much more comfortable way to treat a devastating illness. So, our experience, our global network, we think will increase the probability of success with these vaccines and should they be approved by the agencies we will get them in the hands of physicians to treat patients with cancer. Dr. McPherson: I actually think, Matt, is reticent to comment on some of the really superior attributes of Merck KGaA and particularly, frankly, EMD. EMD, in particular, in the United States with whom we'll be working very heavily in relation to the oncology market, is an aggressive company, which is committed to the development of oncology products. They also have an entrepreneurial spirit which fits very well with Biomira's culture and we believe that combining these two groups, our two companies, with their substantial experience in the clinical and regulatory, as well as developing experience in marketing, sales and distribution along with our research and development background, particularly in immunotherapeutics and our world leading area of development in relation to cancer vaccines is going to be, as they say, a marriage made in heaven. Announcer: Our second question is from a caller, Brian Bapty. Go ahead. Question: Hi guys and congratulations with your partnership, just a quick question, I mean, I guess it's no surprise that you didn't break out the details there, a lot of these things aren't publicized but do you think of that $150 million you could give us a little bit of a breakdown as to what you?ll see, sort of, before filing, after filing and how much, sort of, will be contributed to assisted research? Matt Emmens: We are reluctant to get into the details, as you point out, I can tell you that they are milestone based, they are based on registration, they are based on approval and certain marketing milestones post approval. The total value of the deal would be in excess of $150 million should the products be as successful as we think they would be. That is the amount of detail we would get into today. Dr. McPherson: And I suppose we can say that there is an upfront equity investment in Biomira and as well a cash contribution on the upfront side. Announcer: Our next question is also from a caller. Go ahead. Question: Yes, on the equity component because it will come out next quarter anyhow, how was equity was taken? Dr. McPherson: Ha ha. Matt Emmens: Go ahead Alex. Dr. McPherson: After you, Hortense. Announcer: Could we turn down the volume of the callers, just a little bit? It's very, very loud. Dr. McPherson: It's certainly less than 5% and that's about all we can say at this point in time. Matt Emmens: We have the ability to increase our share, but no more than 19% over time as Merck KGaA chooses. Announcer: Our next question is also from the Internet. Question: Does the Biomira collaboration bring as much value as the Imclone deal did to Merck? Matt Emmens: I would say, with some caution, it could. It's always nice to have hindsight in the pharmaceutical industry and say how brilliant you were when you make a deal like this. The pharmaceutical business is full of risk. As you are early in trials you know, in phase I we give most products less than a 10% chance, as we get into phase II we give them somewhere in the 20 to 30% chance and in phase III we give them a 70-75% chance. So, as we look at these products, they're in phase III however we treat them and think of them more as a phase II. It's a large trial, a well designed trial, by the way, it's a FDA Fast Track trial and these drugs could be successful but at the same time value in a deal is tricky and fraught with difficulty. The markets, should the products work, are among the largest in cancer, the need by patients is among the greatest and we hope for the best. Dr. McPherson: As our investors certainly know because they've been very patient in relationship to us moving forward with this alliance, we have waited and looked at a wide variety of potential alliances and I can say without equivocation that this is as good an alliance as we have seen in the marketplace in the recent past. Announcer: The next question is from a caller, Wayne Schnarr. (Dog barking) Dr. McPherson: You've changed Wayne. Announcer: Go ahead caller. Question: For Matt, could you describe the products you are currently marketing in the United States? Matt Emmens: In the United States, Merck KGaA or EMD markets nothing directly. We are in, we have 100 people in Durham, North Carolina, the primary numbers of those people are involved in drug development for Merck's pipeline, which is promising. You may know that Merck KGaA licensed Glucophage or metformin to BMS which is one of the largest selling diabetes drugs in the world. We have also recently licensed an antidepressant to Smith-Kline-Glaxo. So our research has been productive, however we are choosing to stay in very focused areas and those two areas are primarily oncology and metabolism; which would include diabetes and obesity. Announcer: Our next question, also from the Internet. Question: You said EMD will lead Merck KGaA's oncology efforts; can you describe more about this role? Matt Emmens: Yes, the unique history of Merck, as I said, Merck & Company and Merck KGaA go back to the 1800's when the Merck family owned the whole business. Merck & Company were split off due to World War I and the capturing of the assets of Merck, so Merck KGaA is really the parent company of Merck & Company. That history is important because Merck chose not to be in the pharmaceutical business since World War I in the United States until the 80's when we started purchasing assets which include Dey Pharmaceuticals in California, Lexigen Pharmaceuticals in Boston, Massachusetts and other holdings, Park in the generic business. And as we've gathered these assets it's become apparent that Merck's pipeline will be fruitful and you have to be in the United States to be in the global pharmaceutical market, it's generally about half or 40% of the global market. And as these products come through the pipeline, we have to establish both a development presence here, so that it can be tried in American populations, these products and eventually a marketing force. So we run the worldwide oncology business here but we're also in the business of setting up a fully functional pharmaceutical company from research done in Boston to development done primarily in Durham and throughout the world by Merck KGaA and ultimately commercialization which will involve a marketing and sales, and a sales force in place calling on physicians in the United States. End of part I
Bullboard Posts